Every 8-K that 10x Genomics, Inc. (TXG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TXG filings page.
10x Genomics reported second-quarter 2026 results with revenue of $151.0 million, down from $172.9 million a year earlier. Excluding $1.6 million and $27.3 million of non-recurring patent litigation settlement revenue in 2026 and 2025, respectively, revenue increased 3% over the prior-year quarter. Gross margin improved to 74% from 72%, driven by lower manufacturing costs including $2.6 million of tariff refunds and lower inventory write-downs, partly offset by reduced non-recurring license and royalty revenue.
Operating expenses were $132.1 million, up 39% from $95.0 million, primarily because the current quarter reflected a $3.4 million gain on settlement versus $40.7 million a year ago; excluding settlement impacts, operating expenses were approximately flat year over year. The company recorded an operating loss of $19.6 million and a net loss of $17.9 million, compared with operating income of $30.1 million and net income of $34.5 million in the prior-year period. Cash, cash equivalents and marketable securities totaled $552.0 million as of June 30, 2026. 10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, representing 2% to 5% growth over 2025 excluding non-recurring settlement revenue, and highlighted the acquisition of Proteintech Genomics and new cancer diagnostics collaborations.
10x Genomics, Inc. reported the results of its 2026 annual meeting of stockholders held via live webcast on June 4, 2026. Stockholders representing 198,815,518 votes, or approximately 90.5% of the 219,700,782 eligible votes, were present in person or by proxy, constituting a quorum.
Three Class I directors were elected to three-year terms expiring at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
10x Genomics reported first quarter 2026 results with modest revenue pressure but improved profitability. Revenue was $150.8 million, down 3% from the prior-year quarter, but up 9% when excluding $16.8 million of one-time license and royalty revenue recognized in the first quarter of 2025 related to patent litigation settlements.
Gross margin improved to 70% from 68%, helped by lower warranty costs and inventory write-downs and partially offset by lower license and royalty revenue. Operating expenses fell 15% to $123.2 million from $144.8 million, mainly due to lower outside legal and personnel expenses, leading to a narrower operating loss of $17.0 million versus $39.3 million a year earlier. Net loss improved to $13.5 million from $34.4 million.
The company ended March 31, 2026 with $539.8 million in cash, cash equivalents and marketable securities. It maintained full-year 2026 revenue guidance of $600 million to $625 million, which represents 0% to 4% growth over 2025 when excluding non-recurring 2025 license and royalty revenue. 10x also launched its new Atera spatial platform and announced the STELA spatial data initiative in partnership with Bioptimus.
10x Genomics reported modest revenue growth but sharply improved profitability for 2025. Revenue was $166.0 million in Q4 2025, up 1% year over year, with full-year revenue of $642.8 million, a 5% increase from 2024. Excluding $44.1 million of non-recurring patent litigation settlement revenue, full-year revenue was $598.7 million, a 2% decline.
Q4 gross margin improved to 68% and full-year gross margin to 69%. Operating expenses fell 18% in Q4 and 17% for the year, helped by lower legal and personnel costs and a $49.9 million litigation settlement gain. Net loss narrowed to $16.3 million in Q4 2025 from $49.0 million a year earlier, and to $43.5 million for 2025 from $182.6 million in 2024.
The company ended 2025 with $523.4 million in cash, cash equivalents and marketable securities. For 2026, 10x Genomics guides to revenue of $600–$625 million, which represents 0% to 4% growth versus 2025 after excluding non-recurring patent-related revenue.
10x Genomics, Inc. filed a report stating that it has issued a press release with preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The press release, dated January 11, 2026 and attached as Exhibit 99.1, covers key financial information for that quarter and the full year. The company notes that this information is being furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other documents.
10x Genomics (TXG) announced a planned legal leadership transition. Eric S. Whitaker will retire as Chief Legal Officer effective January 1, 2026, after more than eight years with the company. He will remain an employee with reduced compensation and serve as Strategic Counsel, continuing to advise on ongoing legal matters.
Dr. Randy Wu, currently Vice President of Intellectual Property and Litigation, has been appointed General Counsel and Secretary effective January 1, 2026. Wu joined the company in August 2016 following his tenure at Orrick, Herrington & Sutcliffe LLP, and holds a Ph.D. in Biophysics (UCSF) and a J.D. (Stanford). CEO Serge Saxonov highlighted Whitaker’s leadership through key milestones, and emphasized continuity with Wu’s internal promotion.
10x Genomics (TXG) furnished an 8-K announcing quarterly results. The company reported that it issued a press release with financial results for the quarter ended September 30, 2025, and attached it as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.
10x Genomics’ Class A common stock trades on Nasdaq under the symbol TXG. The exhibit list includes the press release dated November 6, 2025 and the Inline XBRL cover page file.